KVUE:BMV
Kenvue Inc
MX$324.00
0.00%
(0.00) 1D
Aug 28, 8:41:55 AM GMT-6 · MXN
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KVUE...
Mkt. cap
36.40B
Avg. vol.
25.00
Volume
0.00
52-wk high
MX$384.00
52-wk low
MX$259.01
No. of employees
22K
Mkt. cap
36.40B
Avg. vol.
25.00
Volume
0.00
52-wk high
MX$384.00
52-wk low
MX$259.01
No. of employees
22K
News stories
From web sources and news partners
AD HOC NEWS
·
2 hours ago
Kimberly-Clark stock gains as Kenvue takeover clears key regulatory hurdles
MarketBeat
·
1 day ago
Empowered Funds LLC Buys Shares of 203,609 Kenvue Inc. $KVUE
Profile
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
About Kenvue Inc
CEO-
Employees21.9K
FoundedFeb 23, 2022
HeadquartersSummit, New Jersey, United States
SectorPersonal care products
Websitekenvue.com